The influence of serial prostate‐specific antigen (PSA) screening on the PSA velocity at diagnosis

A prostate‐specific antigen (PSA) velocity (PSAV) >2 ng/mL during the year before diagnosis has been associated with an increased risk of prostate cancer‐specific mortality (PCSM) after radical prostatectomy (RP) or radiation therapy. The objective of the current study was to examine whether the proportion of men with a PSAV >2 ng/mL per year has changed significantly during the PSA era.

[1]  P. Carroll,et al.  Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. , 2006, Urologic oncology.

[2]  A. D'Amico,et al.  Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. , 2006, The Journal of urology.

[3]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[4]  J. Brooks,et al.  Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[6]  John K Gohagan,et al.  The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. , 2004, Urologic oncology.

[7]  M. Cooperberg,et al.  Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). , 2003, The Journal of urology.

[8]  Laurence R. Paquette,et al.  Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. , 2002, Urology.

[9]  A. Renshaw,et al.  Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. , 2002, Urology.

[10]  T. Pickles,et al.  The changing face of prostate cancer in British Columbia 1988-2000. , 2002, The Canadian journal of urology.

[11]  Harry J de Koning,et al.  Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial , 2002, International journal of cancer.

[12]  A W Partin,et al.  Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. , 2001, The Journal of urology.

[13]  H. Levin,et al.  Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Cummings,et al.  National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. , 1998, Urology.

[15]  D. Bostwick,et al.  Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. , 1998, Mayo Clinic proceedings.

[16]  R. Lamerz,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1997, Anticancer research.

[17]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[18]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[19]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[20]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[21]  G. Chodak,et al.  Assessment of screening for prostate cancer using the digital rectal examination. , 1989, The Journal of urology.

[22]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[23]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[24]  H. Lilja.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[25]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[26]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[27]  U. Roggenbuck,et al.  Migrations in clinical and pathological stage of prostatic carcinoma in patients undergoing radical prostatectomy in the period between 1993 and 2003. , 2005, Collegium antropologicum.

[28]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[29]  M. Terris,et al.  Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. , 1994, British journal of urology.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.